12:00 AM
 | 
Mar 15, 2010
 |  BioCentury  |  Product Development

Finding room for Recentin

Even though Recentin cediranib from AstraZeneca plc did not achieve non-inferiority to Avastin bevacizumab in the Phase II/III HORIZON III trial, the pharma is hopeful that a place exists for the compound in the metastatic colorectal cancer armamentarium based on its ease of use and ability to block lymphogenesis.

But until it analyzes the full dataset and completes a second Phase II/III trial, HORIZON II, AstraZeneca won't know where Recentin might fit in the treatment paradigm.

In its readout of Horizon III last week, the pharma said 20 mg Recentin plus FOLFOX missed the primary endpoint of non-inferiority to Avastin plus FOLFOX on progression-free survival (PFS) in the double-blind, international study to treat first-line metastatic colorectal cancer (mCRC). FOLFOX includes 5-fluorouracil (5-FU), leucovorin and oxaliplatin.

The trial was designed to show either non-inferiority or superiority to Avastin.

Avastin is a humanized mAb against VEGF that is approved in the U.S. and Europe for both first- and second-line mCRC when given in combination with chemotherapy. Avastin binds to VEGF-A and...

Read the full 843 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >